Glenmark Pharmaceuticals has won two prestigious awards from SCRIP, a leading global pharmaceutical and biotech news publication, in London. The company was presented with 'Best Company in Emerging Markets' and 'Best Overall Pipeline' for the year 2011.

Glenn Saldanha, chairman & managing director, said, “On behalf of our 8000 employees worldwide, we are honoured to receive two prestigious distinctions from a reputed organisation like Informa Healthcare, which hosts the SCRIP Awards. We are specially delighted at having bagged the 'Best Overall Pipeline' distinction which is a testimony of our world-class R&D capabilities and an enormous tribute to all our research staff around the world who have committed themselves over many years to the development of our innovative pipeline”.

While announcing the nominations for Glenmark, SCRIP magazine commented, “Glenmark is a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-class. Its achievements over the year included a major deal with Sanofi in Crohn's disease, completing Phase III trials of its first novel product, crofelemer and demonstrated higher sales and profits growth.